Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
Sharon Griswold, MD, MPH, Mustfa K. Manzur, MD, MPH, MS, and Wendy Dean, MD
Practice ownership shifts to various employment models have amplified the problem of physician-employees of some US health care companies not knowing about services billed in their names.
More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
Dr Isa Ryan joins Ethics Talk to discuss her article, coauthored with Dr Ashish Premkumar and Professor Katie Watson: “Why the Post-Roe Era Requires Protecting Conscientious Provision as We Protect Conscientious Refusal in Health Care.”